Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
June 21, 2024 08:05 ET
|
Starton Therapeutics
100% of patients enrolled achieved a partial response or betterMilder and less frequent drug-related adverse events were observed compared to those associated with Revlimid®No grade 3 or greater...
"I Have Insurance, Why Can't I Afford My Oral Anticancer Medications?" International Myeloma Foundation Highlights the Urgent Need for Cancer Drug Parity Act at Congressional Briefing
June 18, 2024 12:46 ET
|
International Myeloma Foundation
The International Myeloma Foundation-led CIACC hosted a Congressional Briefing addressing the issue of insurance coverage for oral anticancer medications.
Global Multiple Myeloma Markets, 2018-2034: Epidemiology, Pipeline Drugs, Challenges, Opportunities, Reimbursement Scenario, Unmet Needs, and More
June 12, 2024 11:37 ET
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
International Myeloma Foundation (IMF) to Honor 2024 Kyle and Durie Achievement Awardees, Dr. Shaji Kumar and Dr. Francesca Gay
June 11, 2024 08:45 ET
|
International Myeloma Foundation
International Myeloma Foundation (IMF) to Honor 2024 Kyle and Durie Achievement Awardees, Dr. Shaji Kumar and Dr. Francesca Gay.
International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on April 18
April 25, 2024 08:45 ET
|
International Myeloma Foundation
On April 18, the International Myeloma Foundation held its 15th Annual Gala at the Edison Ballroom for the first time in New York, hosted by Ray Romano.
Starton Therapeutics Announces Enrollment Completion for STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
April 25, 2024 08:30 ET
|
Starton Therapeutics
Phase 1b data in the first 50% of patients reflect the responses seen in animals and may suggest superiority in both safety and efficacy when compared to oral Revlimid®Anticipate FDA alignment and...
The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS
April 11, 2024 08:45 ET
|
International Myeloma Foundation
IMF's groundbreaking iStopMM Cohort Study unveils predictive model for bone marrow sampling in MGUS, shaping early diagnosis and treatment.
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
April 04, 2024 08:45 ET
|
International Myeloma Foundation
At the conclusion of this year’s Myeloma Action Month, the International Myeloma Foundation (IMF) was truly grateful and overwhelmed by everyone’s support
Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences
March 25, 2024 08:00 ET
|
Starton Therapeutics
PARAMUS, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies...
Lifelong Philanthropist and 17-year Myeloma Survivor John O’Dwyer Elected to the International Myeloma Foundation’s Board of Directors
March 14, 2024 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the...